[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:melanoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":310,"states":346},"Melanoma",257,218,[8,16,23,30,36,42,48,54,60,66,72,78,84,90,96,102,108,114,120,126,132,138,144,151,157,163,169,175,181,187,193,199,204,210,215,220,226,232,238,244,250,256,261,267,273,279,286,292,298,304],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07281924","Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:18:04.640417Z","2026-07-30T01:46:14.417403Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05264974","Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization",[20],"Phase 1","2026-08-26T02:15:20.225313Z","2026-07-24T01:27:14.929882Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06365619","Neoadjuvant Ipilimumab\u002FNivolumab for Patients With Recurrent, High Risk, Resectable Melanoma",[27],"Phase 2","2026-08-26T02:15:17.167444Z","2026-07-05T05:32:16.751740Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT07237594","IL-17 Blockade to Decrease irAEs (REPLAY)",[20],"2026-08-26T02:15:39.267524Z","2026-06-05T00:55:50.372145Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT07584226","A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors",[20],"2026-08-26T02:16:52.995882Z","2026-05-29T15:36:40.197011Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06295159","Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma",[27],"2026-08-26T02:16:58.658552Z","2026-05-05T02:43:29.676335Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT06284590","Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2\u002FL19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients",[27],"2026-08-26T02:18:47.742071Z","2026-05-05T02:43:29.588431Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT05704647","Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases",[27],"2026-08-26T02:19:24.527214Z","2026-05-05T02:43:29.570479Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT05428007","Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma",[27],"2026-08-26T02:19:08.862440Z","2026-05-05T02:43:29.521481Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT07237100","Mirdametinib in Patients With Advanced NF1-mutant Melanoma",[27],"2026-08-26T02:17:41.695983Z","2026-05-05T02:43:29.510066Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT05913388","GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma",[27],"2026-08-26T02:18:19.586423Z","2026-05-05T02:43:29.508149Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT05629546","Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors",[20],"2026-08-26T02:17:43.321968Z","2026-05-05T02:43:29.506221Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT02870244","Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes",[20],"2026-08-26T02:19:13.549512Z","2026-05-05T02:43:29.498267Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT06545682","Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)",[20],"2026-08-26T02:15:31.806698Z","2026-05-05T02:43:29.359423Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT05155033","Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma",[27],"2026-08-26T02:19:27.519777Z","2026-05-05T02:43:29.184021Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT04572451","Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma",[20],"2026-08-03T02:34:41.267177Z","2026-05-05T02:43:29.047934Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT06121180","Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma",[27],"2026-08-26T02:16:54.044282Z","2026-05-05T02:43:29.039725Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT06712927","Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases",[27],"2026-08-26T02:16:01.079019Z","2026-05-05T02:43:29.025021Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT05839912","Excision of Lymph Node Trial (EXCILYNT) (Mel69)",[],"2026-08-26T02:19:10.436356Z","2026-05-05T02:43:28.973827Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT05588453","Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain",[12],"2026-08-26T02:17:58.890423Z","2026-05-05T02:43:28.969263Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":40,"content_modified":137},"NCT06216938","RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis",[136],"Early Phase 1","2026-05-05T02:43:28.542959Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":142,"content_modified":143},"NCT05655312","MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma",[12],"2026-08-26T02:16:04.914942Z","2026-05-05T02:43:28.517603Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":149,"content_modified":150},"NCT03567889","Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB\u002FC\u002FD Melanoma Patients",[148],"Phase 3","2026-08-26T02:16:50.548894Z","2026-05-05T02:43:28.186027Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":155,"content_modified":156},"NCT05136196","BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study",[27],"2026-08-26T02:18:41.390601Z","2026-05-05T02:43:28.127738Z",{"nct_id":158,"title":159,"phases":160,"status":13,"updated_at":161,"content_modified":162},"NCT05026983","Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases",[27],"2026-08-26T02:16:28.221034Z","2026-05-05T02:43:28.123061Z",{"nct_id":164,"title":165,"phases":166,"status":13,"updated_at":167,"content_modified":168},"NCT06246916","A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)",[148],"2026-08-26T02:18:31.164304Z","2026-05-05T02:43:28.113147Z",{"nct_id":170,"title":171,"phases":172,"status":13,"updated_at":173,"content_modified":174},"NCT05498792","Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma",[136],"2026-08-26T02:16:56.877406Z","2026-05-05T02:43:27.953639Z",{"nct_id":176,"title":177,"phases":178,"status":13,"updated_at":179,"content_modified":180},"NCT02621021","A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab",[27],"2026-08-26T02:16:47.762107Z","2026-05-05T02:43:27.914184Z",{"nct_id":182,"title":183,"phases":184,"status":13,"updated_at":185,"content_modified":186},"NCT01638676","A Phase I\u002FII Trial of Vemurafenib and Metformin to Melanoma Patients",[12],"2026-08-26T02:18:30.351130Z","2026-05-05T02:43:27.855961Z",{"nct_id":188,"title":189,"phases":190,"status":13,"updated_at":191,"content_modified":192},"NCT04119024","Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors",[20],"2026-08-26T02:17:50.500039Z","2026-05-05T02:43:27.844111Z",{"nct_id":194,"title":195,"phases":196,"status":13,"updated_at":197,"content_modified":198},"NCT05968690","Naltrexone and Propranolol Combined With Immunotherapy",[20],"2026-08-26T02:18:56.409949Z","2026-05-05T02:43:27.828228Z",{"nct_id":200,"title":201,"phases":202,"status":13,"updated_at":179,"content_modified":203},"NCT05779423","Cryoablation+Ipilimumab+Nivolumab in Melanoma",[27],"2026-05-05T02:43:27.802169Z",{"nct_id":205,"title":206,"phases":207,"status":13,"updated_at":208,"content_modified":209},"NCT03860883","Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma",[],"2026-08-26T02:15:04.877798Z","2026-05-05T02:43:27.744658Z",{"nct_id":211,"title":212,"phases":213,"status":13,"updated_at":179,"content_modified":214},"NCT05727904","Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.",[148],"2026-05-05T02:43:27.643857Z",{"nct_id":216,"title":217,"phases":218,"status":13,"updated_at":142,"content_modified":219},"NCT06594991","A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma",[27],"2026-05-05T02:43:27.641417Z",{"nct_id":221,"title":222,"phases":223,"status":13,"updated_at":224,"content_modified":225},"NCT06264180","VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]",[148],"2026-08-26T02:15:40.343619Z","2026-05-05T02:43:27.479001Z",{"nct_id":227,"title":228,"phases":229,"status":13,"updated_at":230,"content_modified":231},"NCT03646617","Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma",[27],"2026-08-03T03:26:30.254593Z","2026-05-05T02:43:27.326086Z",{"nct_id":233,"title":234,"phases":235,"status":13,"updated_at":236,"content_modified":237},"NCT04741997","Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma",[136],"2026-08-26T02:17:53.433613Z","2026-05-05T02:43:27.319624Z",{"nct_id":239,"title":240,"phases":241,"status":13,"updated_at":242,"content_modified":243},"NCT06112314","IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)",[148],"2026-08-26T02:15:18.897219Z","2026-05-05T02:43:27.290016Z",{"nct_id":245,"title":246,"phases":247,"status":13,"updated_at":248,"content_modified":249},"NCT07224425","A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it Helps",[20],"2026-08-26T02:16:33.772093Z","2026-05-05T02:43:27.289591Z",{"nct_id":251,"title":252,"phases":253,"status":13,"updated_at":254,"content_modified":255},"NCT04513028","Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma",[],"2026-08-26T02:18:46.137046Z","2026-05-05T02:43:27.173782Z",{"nct_id":257,"title":258,"phases":259,"status":13,"updated_at":21,"content_modified":260},"NCT05549297","Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)",[148],"2026-05-05T02:43:27.069198Z",{"nct_id":262,"title":263,"phases":264,"status":13,"updated_at":265,"content_modified":266},"NCT05361174","A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer",[12],"2026-08-26T02:16:02.918558Z","2026-05-05T02:43:27.066442Z",{"nct_id":268,"title":269,"phases":270,"status":13,"updated_at":271,"content_modified":272},"NCT04594187","Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma",[27],"2026-08-26T02:15:00.557154Z","2026-05-05T02:43:26.987348Z",{"nct_id":274,"title":275,"phases":276,"status":13,"updated_at":277,"content_modified":278},"NCT05970497","A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors",[12],"2026-08-26T02:16:49.565137Z","2026-05-05T02:43:26.979314Z",{"nct_id":280,"title":281,"phases":282,"status":13,"updated_at":284,"content_modified":285},"NCT06697301","Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.",[283],"Phase 2\u002FPhase 3","2026-08-26T02:15:54.846520Z","2026-05-05T02:43:26.952939Z",{"nct_id":287,"title":288,"phases":289,"status":13,"updated_at":290,"content_modified":291},"NCT07288112","DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma",[12],"2026-08-26T02:15:10.362237Z","2026-05-05T02:43:26.907798Z",{"nct_id":293,"title":294,"phases":295,"status":13,"updated_at":296,"content_modified":297},"NCT06624644","A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma",[283],"2026-08-26T02:18:29.369233Z","2026-05-05T02:43:26.766570Z",{"nct_id":299,"title":300,"phases":301,"status":13,"updated_at":302,"content_modified":303},"NCT07287917","Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors",[12],"2026-08-26T02:17:46.653867Z","2026-05-05T02:43:26.754450Z",{"nct_id":305,"title":306,"phases":307,"status":13,"updated_at":308,"content_modified":309},"NCT05077137","A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy",[20],"2026-08-26T02:15:57.572488Z","2026-05-05T02:43:26.754316Z",[311,315,319,323,327,331,335,339,343],{"biomarker":312,"count":313,"slug":314},"BRAF Gene",22,"braf-gene",{"biomarker":316,"count":317,"slug":318},"MSI1 Gene",10,"msi1-gene",{"biomarker":320,"count":321,"slug":322},"MRC1 wt Allele",8,"mrc1-wt-allele",{"biomarker":324,"count":325,"slug":326},"Programmed Cell Death 1 Ligand 1",7,"programmed-cell-death-1-ligand-1",{"biomarker":328,"count":329,"slug":330},"HLA Class I Histocompatibility Antigen, A-0201 Alpha Chain",6,"hla-class-i-histocompatibility-antigen-a-0201-alpha-chain",{"biomarker":332,"count":333,"slug":334},"TPM2 wt Allele",5,"tpm2-wt-allele",{"biomarker":336,"count":337,"slug":338},"GTPase KRas",4,"gtpase-kras",{"biomarker":340,"count":341,"slug":342},"NF1 Gene",3,"nf1-gene",{"biomarker":344,"count":341,"slug":345},"NRAS Gene","nras-gene",[347,351,355,359,363,367,371,375,379,383,386,390,394,398,402,405,409,412,415,419,423,427,430,433],{"state":348,"count":349,"slug":350},"Texas",92,"texas",{"state":352,"count":353,"slug":354},"California",84,"california",{"state":356,"count":357,"slug":358},"Florida",64,"florida",{"state":360,"count":361,"slug":362},"New York",63,"new-york",{"state":364,"count":365,"slug":366},"Pennsylvania",61,"pennsylvania",{"state":368,"count":369,"slug":370},"Ohio",42,"ohio",{"state":372,"count":373,"slug":374},"Michigan",40,"michigan",{"state":376,"count":377,"slug":378},"Tennessee",39,"tennessee",{"state":380,"count":381,"slug":382},"Colorado",36,"colorado",{"state":384,"count":381,"slug":385},"New Jersey","new-jersey",{"state":387,"count":388,"slug":389},"Massachusetts",35,"massachusetts",{"state":391,"count":392,"slug":393},"Virginia",34,"virginia",{"state":395,"count":396,"slug":397},"North Carolina",32,"north-carolina",{"state":399,"count":400,"slug":401},"Illinois",30,"illinois",{"state":403,"count":400,"slug":404},"Minnesota","minnesota",{"state":406,"count":407,"slug":408},"Arizona",29,"arizona",{"state":410,"count":407,"slug":411},"Missouri","missouri",{"state":413,"count":407,"slug":414},"Washington","washington",{"state":416,"count":417,"slug":418},"Maryland",27,"maryland",{"state":420,"count":421,"slug":422},"Utah",25,"utah",{"state":424,"count":425,"slug":426},"Wisconsin",24,"wisconsin",{"state":428,"count":313,"slug":429},"Georgia","georgia",{"state":431,"count":313,"slug":432},"Kentucky","kentucky",{"state":434,"count":435,"slug":436},"Connecticut",20,"connecticut"]